Payment overview · 2025
General Payments
$1,529.74
82 reported records · 17 companies
Healthcare provider profile · identity verified
Vicki L Moore, MD
Allopathic & Osteopathic Physicians|Family Medicine · BIRMINGHAM, AL · NPI 1942349220
Verified facts
What the public records show
CMS Open Payments records show Vicki L Moore, MD received $1,529.74 in general payments during 2025 across 82 reported records.
PFIZER INC. accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $334.03 | 21.8% | 19 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $272.61 | 17.8% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $183.34 | 12.0% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $163.74 | 10.7% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $149.57 | 9.8% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.28 | 3.7% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $50.32 | 3.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.62 | 3.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.46 | 3.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $41.94 | 2.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.56 | 2.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.71 | 1.9% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $27.24 | 1.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $24.44 | 1.6% | 1 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $24.06 | 1.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.10 | 1.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.72 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,529.74 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $297.13 | 17 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $252.91 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $183.34 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $174.24 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.36 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $122.89 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $86.09 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $74.23 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $56.28 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.32 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $47.72 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $47.62 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $41.94 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.38 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $36.90 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.90 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.90 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.71 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.67 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.91 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.91 | 2 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $27.24 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| IMMULITE 1000 Immunoassay System Normalized: immulite 1000 immunoassay system |
Device | Siemens Medical Solutions USA, Inc. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 29 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 161 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 116 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
71 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
161 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 115 |
| Alprazolam | Alprazolam | 288 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 267 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 83 |
| Zolpidem Tartrate | Zolpidem Tartrate | 205 | 48 |
| Losartan Potassium | Losartan Potassium | 193 | 66 |
| Omeprazole | Omeprazole | 193 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 57 |
| Clonazepam | Clonazepam | 162 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 56 |
| Lisinopril | Lisinopril | 161 | 51 |
| Mounjaro | Tirzepatide | 161 | 27 |
| Trazodone Hcl | Trazodone Hcl | 160 | 53 |
| Montelukast Sodium | Montelukast Sodium | 154 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 47 |
| Gabapentin | Gabapentin | 121 | 43 |
| Metformin Hcl Er | Metformin Hcl | 119 | 37 |
| Ozempic | Semaglutide | 116 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 32 |
| Tramadol Hcl | Tramadol Hcl | 106 | 29 |
| Meloxicam | Meloxicam | 100 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 33 |
| Bupropion Xl | Bupropion Hcl | 97 | 29 |
| Potassium Chloride | Potassium Chloride | 96 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 30 |
| Sertraline Hcl | Sertraline Hcl | 91 | 32 |
| Valsartan | Valsartan | 82 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 43 |
| Atenolol | Atenolol | 76 | 24 |
| Lorazepam | Lorazepam | 74 | 22 |
| Synthroid | Levothyroxine Sodium | 71 | 22 |
| Simvastatin | Simvastatin | 69 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 68 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 65 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 14 |
| Ezetimibe | Ezetimibe | 58 | 17 |
| Temazepam | Temazepam | 58 | 11 |
| Estradiol | Estradiol | 56 | 24 |
| Metformin Hcl | Metformin Hcl | 56 | 21 |
| Celecoxib | Celecoxib | 54 | 24 |
| Allopurinol | Allopurinol | 52 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 15 |
| Methylprednisolone | Methylprednisolone | 48 | 42 |
| Azithromycin | Azithromycin | 47 | 42 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 47 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 13 |
| Furosemide | Furosemide | 47 | 20 |
| Fluconazole | Fluconazole | 46 | 28 |
| Valacyclovir | Valacyclovir Hcl | 44 | 13 |
| Famotidine | Famotidine | 43 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 15 |
| Carvedilol | Carvedilol | 40 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 30 |
| Azelastine Hcl | Azelastine Hcl | 39 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 14 |
| Clonidine Hcl | Clonidine Hcl | 38 | 14 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Glimepiride | Glimepiride | 37 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 36 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Methocarbamol | Methocarbamol | 33 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | 12 |
| Spironolactone | Spironolactone | 32 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 25 |
| Eliquis | Apixaban | 29 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 21 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 18 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 14 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | 11 |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 11 |
| Cephalexin | Cephalexin | 14 | 11 |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Np Thyroid | Thyroid,pork | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dayvigo | Lemborexant | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,529.74 · 82 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, CAPVAXIVE, COMIRNATY, ELIQUIS, FREESTYLE LIBRE 3, GARDASIL 9, IMMULITE 1000 Immunoassay System, INSPIRE, JARDIANCE, KRYSTEXXA, Kerendia, LAGEVRIO, LEQEMBI, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, RECORLEV, REPATHA, Rybelsus, SHINGRIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error